CD52 and AL amyloidosis: They all received immunotherapy: anti-CD38 mAb for multiple myeloma (daratumumab, n = 1), anti-CD52 mAb for T-cell chronic leukemia (alemtuzumab, n = 1), and anti-CD19 anti-CD3 bispecific mAb for acute lymphoblastic leukemia (blinatumomab, n = 1).